Form EFFECT Tvardi Therapeutics,
Tweet
Share
E-mail| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 13, 2026 |
| Accession Number: | 0001104659-26-057914 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
- Kuaishou Technology to Report 2026 Second Quarter and Interim Financial Results on August 19, 2026
- Intropy Announces $11 Million in Funding to Build the AI-Native Operating System for the Spare Parts Supply Chain
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
